Esophageal Cancer
Conditions
Keywords
Esophageal Cancer, chemoradiotherapy response, molecular factors
Brief summary
1. Retrospective review of old patients * Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 2. Prospective case-control study: RNA sequencing & miRNA microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy * acquirement of tissue, blood, clinical information * isolation of RNA, DNA, serum database of clinical & demographic information \*\*\*Analysis of mRNA sequencing / miRNA sequencing\*\*\*\* first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator 3. Experimental set for qPCR (esophageal tissue) study group 4. TMA for screened exon gene 5. validation set for qPCR (esophageal tissue) 6. follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M) 7. Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors 8. Validate the prediction model.
Detailed description
1. Retrospective review of old patients * Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 Study Group 1. non responder 2. CR but recurrence 3. CR and survival loner than 2 years 2. Prospective case-control study: RNA sequencing & miRNA microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy --\> acquirement of tissue, blood, clinical information --\> isolation of RNA, DNA, serum database of clinical & demographic information study group 1. non-responder (N=14) 2. Complete Remission (N=14) For considering the drop rate, 2-fold screening \*\*\*Analysis of mRNA sequencing / miRNA sequencing\*\*\*\* first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator 3\) Experimental set for qPCR (esophageal tissue) study group 1. non-responder (N=40) 2. complete remission (N=40) 4\) TMA for screened exon gene 5\) validation set for qPCR (esophageal tissue) new esophageal cancer set 1. non-responder (N=30) 2. complete remission (N=30) 6\) follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M) 7\) Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors Test several combination models 1. gene + gene combination, 2. gene + clinical information combination, 3. gene + gene + clinical information combination 8\) Validate the prediction model. 9\) primary organoid culture and prediction of chemoradiotherapy response
Interventions
OTHERchemoradiotherapy
concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
Sponsors
Kyungpook National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Inclusion criteria
1. locally advanced or advanced esophageal cancer who want concomitant chemoradiotherapy 2. persons who assigned the written informed consents.
Exclusion criteria
1. persons who did't assign the informed consents 2. other organ cancer 3. heavy alcoholics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prediction model for CCRT response based on clinical and genetic molecular factors | up to 36 months | prediction model for CCRT response based on clinical and genetic molecular factors in esophageal cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| banking of remained human material for post genetic & molecular study | up to 10 years | banking of remained human material for post genetic & molecular study |
| circulating preditction marker for CCRT response and prognosis | up to 5 years | circulating miRNA sequencing |
| tissue prediction marker for CCRT response and prognosis | up to 5 years | tissue RNA sequencing / tissue microarray |
| in-vitro prediction of CCRT using primary esophageal cancer organoid | up to 6 month | 1. Esophageal cancer derived primary organoid culture 2. treat RT and 5-FU to esophageal cancer organoid 3. measure the response of CCRT (live cell/dead cell) * This process is in-vitro process, not in-vivo experiment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Clinical prediction factors for CCRT response (retrospective study) | up to 5 years | Evaluation of clinical prediction factors for CCRT response in esophageal cancer from 2005-2015 (retrospective study) |
Countries
South Korea
Contacts
Primary ContactSu Youn Y Nam, MD, PhD
Outcome results
None listed